NCT06560112View on ClinicalTrials.gov

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Recurrent Ovarian Cancer
Interventions
DRUG

AK104

ivgtt

DRUG

AK112

ivgtt

DRUG

Chemotherapy

ivgtt

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY